Avraham Ben-Tzvi - 23 Dec 2025 Form 4 Insider Report for Indaptus Therapeutics, Inc. (INDP)

Reporting relationship: Director
Issuer ticker: INDP
Reported as of: 23 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jan 2026, 21:57:06 UTC
Prior SEC filing: 23 Dec 2025
Next SEC filing: 28 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Avraham Ben-Tzvi

Key filing fact

Avraham Ben-Tzvi filed Form 4 for Indaptus Therapeutics, Inc. (INDP) on 22 Jan 2026.

Key facts

This page summarizes Avraham Ben-Tzvi's Form 4 filing for Indaptus Therapeutics, Inc. (INDP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Jan 2026, 21:57.

Change

Previous filing in this sequence was filed on 23 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001944721 Primary reporting owner

Ben-Tzvi Avraham

Relationship: Director
Address: 44 ZAYT SHEMEN ST., FLAT 4, EFRAT, ISRAEL
Signature: /s/ Avraham Ben-Tzvi
Signature date: 22 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INDP transaction

Common Stock

Award

Transaction value: $0
Shares: +25,000
Change %: +25000%
Price: $0.000000
Shares after: 25,100
Date: 20 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INDP transaction Derivative

Option to Buy Common Stock

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 23 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $1.95
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person acquired 25,000 shares of restricted common stock of the Issuer pursuant to a consulting agreement dated January 20, 2026, which shares vested 100% upon grant.

Footnote F2

Includes 100 shares of common stock of the Issuer held in a Roth IRA.

Footnote F3

The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program. The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Board through each vesting date.